
Tirzepatide significantly reduced body weight, fat mass, and lean mass in participants with obesity or overweight. In this substudy of 160 participants from the SURMOUNT‐1 trial, tirzepatide (n=124) led to a 21.3% reduction in body weight, 33.9% in fat mass, and 10.9% in lean mass, compared to placebo (n=36), which showed 5.3%, 8.2%, and 2.6% reductions, respectively (p<0.001). Fat mass loss was predominant across subgroups.
Like
Save
Share